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Abstract
Background:  Gaucher disease is a potentially severe lysosomal storage disorder caused by
mutations in the human glucocerebrosidase gene (GBA). We have developed a multiplexed genetic
assay for eight diseases prevalent in the Ashkenazi population: Tay-Sachs, Gaucher type I, Niemann-
Pick types A and B, mucolipidosis type IV, familial dysautonomia, Canavan, Bloom syndrome, and
Fanconi anemia type C. This assay includes an allelic determination for GBA allele c.1448T>C
(L444P). The goal of this study was to clinically evaluate this assay.
Methods:  Biotinylated, multiplex PCR products were directly hybridized to capture probes
immobilized on fluorescently addressed microspheres. After incubation with streptavidin-
conjugated fluorophore, the reactions were analyzed by Luminex IS100. Clinical evaluations were
conducted using de-identified patient DNA samples.
Results: We evaluated a multiplexed suspension array assay that includes wild-type and mutant
genetic determinations for Gaucher disease allele c.1448T>C. Two percent of samples reported
to be wild-type by conventional methods were observed to be c.1448T>C heterozygous using our
assay. Sequence analysis suggested that this phenomenon was due to co-amplification of the
functional gene and a paralogous pseudogene (ΨGBA) due to a polymorphism in the primer-binding
site of the latter. Primers for the amplification of this allele were then repositioned to span an
upstream deletion in the pseudogene, yielding a much longer amplicon. Although it is widely
reported that long amplicons negatively impact amplification or detection efficiency in recently
adopted multiplex techniques, this assay design functioned properly and resolved the occurrence
of false heterozygosity.
Conclusion:  Although previously available sequence information suggested GBA gene/
pseudogene discrimination capabilities with a short amplified product, we identified common
single-nucleotide polymorphisms in the pseudogene that required amplification of a larger region
for effective discrimination.
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Background
Gaucher disease is a lysosomal storage disorder caused by
mutations in the human glucocerebrosidase gene
(GBA)[1] (for a review, see Grabowski[2]). There is con-
siderable interest in clinical and research analysis of GBA.
Assay methods have typically involved combinations of
long-template PCR, gel electrophoresis, and southern
blotting [3-5]. While these approaches are effective, there
is a drive to take advantage of the improvements offered
by multiplexed techniques[6]. A common analytical
implementation of multiplexing involves the generation
of multiple amplicons in a single PCR-based assay. Subse-
quent multiplex detection methods range from capillary
electrophoresis to liquid-bead arrays[7,8]. Importantly, it
is well established that amplicon length bears heavily on
amplification efficiency and that many recently adopted
multiplex techniques display a preference for smaller
amplicons [8-14]. Multiplex assays are thus often devel-
oped from well-proven simplex PCR designs by reducing
amplicon length. This and other technical changes present
design challenges and can have unintended consequences
that are not readily revealed in the controlled environ-
ment of the development laboratory.
For example, in order to design new human genetic assays
with smaller amplicons, ample nucleotide sequence data
sets are required. However, the sequence information
required for quality design may not always be readily
available, particularly in regard to the genomic diversity
present in a given population. In the case of GBA, there are
relatively few publicly available unique genomic DNA
sequences[1,15,16]. Sequences derived from cDNA are
more abundant[17] but are not so useful as a design aid
for assays targeting genomic DNA. Such design challenges
in clinical molecular analysis of GBA are well estab-
lished[5]. For example, a pseudogene (ΨGBA) exists
downstream of GBA that is 96% identical to the func-
tional gene[1]. Although ΨGBA is expressed[18], the pres-
ence of various defects, including a 55-bp deletion in exon
9, predict that it encodes a non-functional protein[1].
Interestingly, in all sequences reported to date ΨGBA also
has an apparent defect paralogous to the 1448 T to C tran-
sition (c.1448T>C) that codes for a leucine to proline sub-
stitution at position 444 (L444P) in GBA[1,15,16]. When
found in the functional gene, the c.1448T>C mutation
can cause disease[19] and has been demonstrated in one
system to reduce enzymatic activity by 77%[20]. In order
to accurately perform genetic analysis of GBA, it is there-
fore imperative to distinguish the functional gene from
the pseudogene. Unfortunately, the c.1448T>C transition
falls in a region of very high identity between GBA and
ΨGBA. Attempts to address this issue have involved assay
systems amenable to large amplicons, such as restriction
digest with gel electrophoresis, gene sequencing, or selec-
tive amplification using the upstream 55-bp deletion
within ΨGBA. However, these designs are not predicted to
be ideal for more recently developed techniques – such as
real-time PCR and suspension bead arrays – that are being
adopted by high-throughput clinical laboratories[3-5,8-
14,21].
Using publicly available genomic DNA sequences
[1,15,16], we developed multiplexed suspension bead
array reagents to characterize alleles covering 8 diseases
that are highly prevalent in the Ashkenazi Jewish popula-
tion. The diseases assayed have a collective carrier fre-
quency of 1:6 in this population: Tay-Sachs, Gaucher type
I, Niemann-Pick types A and B, mucolipidosis type IV,
familial dysautonomia, Canavan, Bloom syndrome, and
Fanconi anemia type C. While assays for these diseases
have generally involved multiple diagnostic platforms [3-
5,22], the Signature Ashkenazi Carrier Panel (ACP) rea-
gents allow for simultaneous genetic determinations of all
diseases. This report details our identification of common
ΨGBA and GBA polymorphisms not reported in the liter-
ature. These results demonstrate the importance of clini-
cal evaluation and assay redesign in reducing the false
positive frequency in a multiplex genetic test.
Methods
Reagents and samples
Solutions of 1M Tris-HCl, pH 8.0, 1X TE (10 mM Tris, 1
mM EDTA, pH 8.0), 10 % SDS, Signature Amp Mix I and
nuclease-free water were obtained from Ambion Diagnos-
tics (Austin, TX). Uracil-N-Glycosylase (HK-UNG) was
obtained from EpiCentre (Madison, WI). AmpliTaq Gold
and 10X Gold Buffer were obtained from Applied Biosys-
tems (Foster City, CA). Deoxynucleotides were obtained
from Bioline (Randolf, MA). Tetramethyl ammonium
chloride (TMAC), sodium sarkosyl, and 2-(N-Mor-
pholino)ethanesulfonic acid (MES) were purchased from
Sigma (St. Louis, MO). The MES was adjusted to pH 4.5
by addition of 5 N NaOH then stored at 4C. Streptavidin-
β-phycoerythrin (SA-PE) was obtained from ProZyme
(Alameda, CA). EDC, (1-ethyl-3-[3-dimethylaminopro-
pyl] carbodiimide hydrochloride), was obtained from
Pierce (Rockford, IL). xMAP carboxylated microspheres
were obtained from Luminex (Austin, TX). Human
genomic DNA samples obtained from the Coriell Institute
for Medical Research (Camden, NJ) were purchased as
DNA isolated from cell lines. Oligonucleotides were syn-
thesized by Biosearch Technologies (Novato, CA). All oli-
gonucleotides were reverse-phase cartridge purified and
prepared as 100 μM stock solutions in deionized water.
Residual patient genomic DNA samples were used in this
study. Samples were randomly selected and provided
without coding or identifying information to members of
the research team. Investigators were not provided with
previously determined genotypes until after testing was
completed. In addition, the investigators did not haveBMC Medical Genetics 2006, 7:69 http://www.biomedcentral.com/1471-2350/7/69
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access to the laboratory information systems of the facili-
ties.
PCR amplification
PCR reactions were prepared in 50-μL volumes using 5
mM Mg2+, 5 U of AmpliTaq Gold, 0.1 U of HK-UNG, and
amplification primers. Either 0.8 pmol of each primer
GDL444P-US1 and GDL444P-DS1 or, after clinical evalu-
ations and redesign, 1.6 pmol of each primer GDL444P-
U6 and GDL444P-DS1 was included. PCR primers for
array detection and primers for sequencing are listed in
Table 1. The final nucleotide mixture was 0.2 mM dATP,
dCTP, and dGTP, 0.05 mM dTTP, and 0.4 mM dUTP.
Reactions consisted of incubation of UNG at 37C for 15
minutes, then activation of AmpliTaq Gold enzyme for 10
minutes at 95C followed by amplification over 35 cycles
of 94C for 30 s, 61C for 90 s, and 72C for 90 s, followed
by 72C for 2 minutes. Single-tube multiplex reactions
were performed with primers to amplify alleles in the Sig-
nature ACP assay (data not shown). Sample identities
were irreversibly blinded to laboratory members. These
de-identified patient DNA samples were prepared via
either Qiagen BioRobot 9604 or Genovision automated
methods according to manufacturer directions. A total of
5 uL of patient DNA sample was used per reaction. DNA
samples were not quantified.
Capture probe coupling
Oligonucleotide capture probes were modified at the 5'
terminus with an aminododecyl group to allow conjuga-
tion to the carboxylated microspheres. The probes used
are listed in Table 1. Covalent attachment of the amine
modified probe to the carboxyl groups on the surface of
the fluorescently addressed microspheres were completed
using a standard carbodiimide coupling procedure[23].
Briefly, 5 × 106 microspheres were pelleted, resuspended
in 50 μL of 100 mM MES, pH 4.5, then mixed with 200
pmol of aminododecyl-modified oligonucleotide. A 2.5
μL aliquot of 10 mg/mL EDC was added, the solution
briefly vortexed and allowed to incubate for 5 minutes. A
fresh 10 mg/mL solution of EDC was prepared for a sec-
ond addition of EDC and 5 minute incubation. The
microspheres were then washed with 0.02% Tween-20,
then with 0.1% SDS, and then resuspended in 100 μL of
1X TE buffer, pH 8.0. Coupled microspheres were stored
at 4C in the dark.
Bead-array hybridization
A multiplex bead array containing c.1448T, c.1448T>C,
and 43 additional capture probes was prepared in 1X
hybridization buffer (3.0 M TMAC, 50 mM Tris-HCl, 4
mM EDTA, and 0.1% Sarkosyl, pH 8.0) such that each of
the 45 beads was at a final concentration of 100 beads/uL.
Samples were analyzed by mixing 48 μL of the bead solu-
tion with a 2 μL portion of amplified products. The sam-
ples were hybridized at 95C for 5 minutes and 52C for 25
minutes. Following hybridization, the samples were
immediately transferred to a heat block pre-equilibrated
to 52C on the XYP stage of a Luminex 100 System. This
was followed by the addition of 25 μL of a 40 ng/μL SA-
PE solution that had been freshly diluted in 0.75X hybrid-
ization buffer (2.25 M TMAC, 37.5 mM Tris-HCl, 3 mM
EDTA, and 0.075% Sarkosyl, pH 8.0). Median fluores-
cence intensity (MFI) values were obtained from a mini-
mum of 100 beads. Allele ratios were calculated as the
fraction of fluorescent signal of the test allele divided by
the sum of all fluorescent signals in the allele group. For
the c.1448T>C mutation, this could be expressed as:
MFIc.1448T>C/(MFIc.1448T>C + MFIC.1448T). Allele ratios and
genetic determinations were confirmed by using the con-
figurable software tool Signature Script version 2.0 (Asur-
agen, Austin, TX). This software package can address
ethical and policy considerations by revealing only those
alleles and/or diseases which have been requested by the
physician or genetic counselor. This software package also
allows configuration of analysis parameters, stores test
data in a database, queries the database with or without
sample identifiers, and produces sample and batch
reports.
DNA sequencing
The c.1448T>C regions of the GBA gene and ΨGBA pseu-
dogene were amplified using PCR primers GDL444P-U6
with GDLseq-L2 or GDLseq-U4 with GDLseq-L1, respec-
tively (see Table 1). PCR was completed using 2.5 U
SuperTaq (Ambion), 1 ng template DNA, and 10 pmol
each primer. Reactions consisted of 35 cycles of 94C for
30 s, 58 for 30 s, and 72C for 60 s followed by 2 minutes
at 72C. PCR products were purified using a QIAquick PCR
Purification Kit (Qiagen). Purified products were verified
on Agilent Bioanalyzer for purity then were sent to ACTG,
Inc. (Northbrook, IL) for dye-terminator DNA sequencing
using each amplification primer. Sequences were aligned
using the BCM Search Launcher web-based Multiple
Sequence Alignment (ClustalW 1.8) application[24]. The
alignment was formatted using Boxshade 3.21[25] with
the following command line: "ulimit -t 30; box -def -num-
def -out=wwwtmp/1.BOX.4270.9603.rtf -in=wwwtmp/
Table 1: Oligonucleotides used in this work
Primer Name 5' to 3' Sequence
GDL444P-DS1 Biotin-TTTAGCACGACCACAACAGC
GDL444P-US1 CATCTGTTCCCACATTCAGC
GDL444P-U6 GGTGCGTAACTTTGTCGACAGTCC
GDLwt Aminododecyl-AGAACGACCTGGACGCAG
GDLmut Aminododecyl-AGAACGACCCGGACGCAG
GDLseq-L1 AAGCTGAGAGTGTGATCCTGCCAA
GDLseq-L2 CCACAGCAGGATCCTTGATGGTAA
GDLseq-U4 GGACCGACTGGAACCCATCABMC Medical Genetics 2006, 7:69 http://www.biomedcentral.com/1471-2350/7/69
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1.BOX.4270.9603.ali -par = pt10.par -type = 1 -dev = 4 -
thr = 0.8 >/dev/null".
Results
With the goal of creating multiplexed techniques to offer
reduced turnaround time and cost in multiple-disease
assessment,[6] we developed a highly multiplexed sus-
pension array to simultaneously identify 22 wild-type and
23 mutant alleles covering 8 diseases that are highly prev-
alent in the Ashkenazi Jewish population. This assay
includes wild-type and mutant genetic determinations for
Gaucher disease alleles c.1226A>G (N370S), 84GG,
IVS2+1G>A, and c.1448T>C (L444P). In the assay, the
c.1448T>C-containing region of the GBA gene was ampli-
fied by multiplex PCR using biotinylated primers. When
amplifying GBA, it was crucial to distinguish gene from
pseudogene. While the 55-bp deletion in ΨGBA located
502-nt upstream of the T to C transition might be used for
assay systems amenable to large amplicons, [3-5] the
length of amplicon created is not reported to be ideal for
suspension arrays[8,9]. Hence, the design of new primers
for amplifying the c.1448T>C region relied on reported
sequence divergence between GBA and ΨGBA. The
upstream primer was predicted to pair with both GBA and
ΨGBA sequences. However, the downstream primer
spanned nucleotide 7368 with its 3' terminus at nucleo-
tide 7354 (reference sequence [GenBank:J03059.1]; [see
additional file 1], Multiple sequence alignment of GBA
and ΨGBA). The predicted 3' mispairing is expected to
allow selective amplification of the gene and not the pseu-
dogene [26], thus yielding a 134-bp amplicon based on
GBA sequence. Amplified products were then directly
hybridized to capture probes immobilized on fluores-
cently addressed microspheres[22]. After incubation with
streptavidin-conjugated fluorophore, the reaction mix-
tures were analyzed by the Luminex flow cytometry plat-
form to identify microsphere/amplicon interactions.
Stringency was preserved by maintaining a reaction tem-
perature of 52C. Allele ratios were calculated manually
and by using Signature Script version 2.0 as described in
the Materials and Methods section. Genetic determina-
tions for c.1448T>C were assigned using the following
parameters: allele ratios below 0.22 as normal, between
0.30 and 0.65 as heterozygous, above 0.75 as mutant, and
intervening regions (0.22–0.30, 0.65–0.75) as indetermi-
nate. The representative data shown in Table 2 suggest a
robust methodology for identifying the allele of interest in
DNA samples derived from cell line controls.
Clinical evaluations were carried out to assess concord-
ance with techniques already established in multiple ref-
erence laboratories. We expected to detect c.1448T>C at a
frequency similar to that based on meta-analysis of the lit-
erature: between 1:340 and 1:1,200 (Table 3). At two
independent clinical laboratories, Gaucher c.1448T>C
allelic determinations were made for a total of 614 sam-
ples. Thirteen samples were observed to be heterozygous
using our assay (see Table 4). All normal genotypes were
concordant with independent results based on estab-
lished, laboratory-validated methods reported by each
respective laboratory (data not shown). However, all
c.1448T>C heterozygous determinations (2.1%, 1:47)
were discrepant with independent results reported by
each respective laboratory. Hence, c.1448T>C hetero-
zygous calls were observed about 7- to 25-fold more often
than expected.
We suspected that the discrepancy was due to co-amplifi-
cation of the functional gene and paralogous pseudogene
due to a polymorphism in the primer-binding site of the
pseudogene in discordant DNA samples. These predic-
tions were borne out experimentally using DNA sequenc-
ing. A de-identified set of four discrepant c.1448T>C
heterozygous samples and two concordant c.1448T nor-
mal samples were characterized further. A GBA gene-spe-
cific upstream primer was located within the paralogous
55 bp absent from exon 9 of ΨGBA. The ΨGBA pseudog-
ene-specific upstream primer spanned the breakpoint of
the 55-bp deletion. The regions of interest were amplified
and sequenced for the GBA gene and ΨGBA pseudogene
from each DNA sample along with a Coriell cell line DNA
(accession number NA11215).
A multiple sequence alignment of the resultant sequences
alongside those reported by Horowitz et al.[1,4] and the
UCSC Genome Bioinformatics database [16] is available
as a supplemental file [see additional file 1]. The sequence
data revealed several nucleotide positions that are not
conserved between GBA and ΨGBA (Table 5). An analysis
of each nucleotide position can be found in the discussion
below.
The nucleotide data observed at nucleotide positions
7354 and 7368 supported our hypothesis that a polymor-
phism in the primer-binding site of the pseudogene could
Table 2: Representative fluorescence and allele ratio 
developmental data
MFI
Cell Line Sample c.1448T c.1448T>C Ratio call
NA03461 1268 36 0.03 Normal
NA09960 1285 10 0.01 Normal
NA16193 1142 71 0.06 Normal
NA00852 1353 110 0.08 Normal
NA11215 1228 53 0.04 Normala
NA10915 57 1804 0.97 c.1448T>C muta, b
aGenotype sequence confirmed (data not shown)
bc.1448T>C homozygous mutantBMC Medical Genetics 2006, 7:69 http://www.biomedcentral.com/1471-2350/7/69
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allow co-amplification with the gene. As expected based
on previous observations [1,15,16], all observed genes
displayed a T at nucleotide 7319 and pseudogenes a C.
Hence, these data further confirmed that if the pseudog-
ene is co-amplified with the wild-type gene, both wild-
type and mutant product will result. This set of products
is then predicted to yield a heterozygous determination in
the detection step.
As the only reliable distinguishing characteristic between
gene and pseudogene, primers for the amplification of the
region containing the c.1448T>C transition were posi-
tioned to span the upstream 55-bp deletion in the pseu-
dogene. Amplification with these primers yielded a 576-
bp amplicon, a length that could result in reduced hybrid-
ization and detection efficiencies in Luminex-based detec-
tion (S Dunbar, Luminex, personal communication; see
also manufacturer recommendations [9]). However, the
larger amplicon containing the c.1448T>C region yielded
fluorescent signal of ~1000 in the hybridization assay as
compared to ~1300 for the original product. Normal
allele ratios for wild-type samples were also similar. Het-
erozygous detection for cell-line and patient samples was
preserved. Heterozygosity due to amplification of the
pseudogene was resolved for the original samples. These
results are summarized in Table 4. Further testing of 280
new de-identified patient samples using this primer pair
resulted in all normal c.1448T normal determinations
(data not shown). Hence, successful detection of the
larger amplicon appears to resolve issues with ΨGBA pol-
ymorphisms in this region.
Discussion
The substantial growth of nucleic acid research in the last
two decades has generated tremendous understanding of
human disease. Advances in appreciation of the complex
genetic factors involved in many diseases hold great
promise for substantial improvements in medical diagno-
sis and treatment, but present challenges to the design of
robust and reliable assays. For example, multifactorial ill-
nesses have been characterized that are influenced by
multiple genetic elements including genes and pseudo-
Table 4: Representative fluorescence and allele ratio clinical data
first design second design
c.1448T c.1448T>C Ratio call c.1448T c.1448T>C Ratio call
patient 4 1108 579 0.34 c.1448T>C heta 1249 54 0.04 Normal
patient 9 1068 585 0.35 c.1448T>C het 1091 93 0.08 Normal
patient 11 1273 679 0.35 c.1448T>C het NDb ND ND ND
patient 14 1229 654 0.35 c.1448T>C het 871 87 0.09 Normal
patient 17 1357 58 0.04 Normal 977 126 0.11 Normal
patient 27 1391 15 0.01 Normal ND ND ND ND
NA10915 57 1804 0.97 c.1448T>C mutc 5 1133 1.00 c.1448T>C mut
NA03461 1268 36 0.03 Normal 1228 0 0.00 Normal
NA08753 NAd NA NA NA 844 603 0.42 c.1448T>C het
ac.1448T>C heterozygous
bNot Determined, limited sample volume exhausted during prior experimentation
cc.1448T>C homozygous mutant
dNot Available at the time of experimentation with first design
Table 3: Review of carrier frequencies of Gaucher allele c.1448T>C
fraction
carriers identified patients assayed decimal 1-in- reference
0 1528 0.00 n/a DeMarchi et al.[38]
4 1364 0.30 340 Eng et al.[39]
3 3764 0.08 1200 Kronn et al.[40]
0 572 0.00 n/a Oddoux et al.[41]
1 546 0.20 550 Eng et al.[42]
3 3764 0.08 1200 Allitto et al.[43]
12 7706 0.10 640 Strom et al.[44]
17 17184 0.10 1010 Horowitz et al.[1]
40 36428 0.11 910 cumulativeBMC Medical Genetics 2006, 7:69 http://www.biomedcentral.com/1471-2350/7/69
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genes[18,27-31]. Study of the blood clotting disorder
thrombophilia, for instance, requires characterization of
numerous alleles within multiple genes that can be con-
founded by the presence of a pseudogene[32]. The com-
plex nature of many such diseases has led to the
development of multifaceted techniques that simultane-
ously examine many analytes. Multiplexing is the term
used to describe the ability to analyze a number of ana-
lytes within a single process or assay. In addition to exam-
ining numerous components of a single disease, these
same multiplex techniques have been adopted into
research and clinical laboratories for assessing multiple
inherited diseases within a given population. The benefits
of consolidating multiple-disease testing into a single pro-
cedure such as the test presented in this work include
reduced training, labor costs, and turnaround time[6].
In the design and evaluation of such reagents, care must
be taken to minimize the occurrence of inaccurate detec-
tion. Accurate detection is desired both scientifically and
ethically, since false positives can lead to unnecessary pro-
cedures, therapy, and psychosocial consequences
[2,33,34].
In the interest of designing a multiplexed technique to
offer reduced turnaround times and cost in the analysis of
inherited diseases prevalent in the Ashkenazi population,
we developed a set of reagents that allows genetic determi-
nations for Gaucher disease alleles c.1226A>G (N370S),
84GG, IVS2+1G>A, and c.1448T>C (L444P). These rea-
gents use multiplex PCR and bead array hybridization to
facilitate an assay that detects 23 mutations per sample in
fewer than 5 hours. Only a single transfer step is required
with no intervening purification steps. Allele stringency is
maintained without post-hybridization wash steps. In our
preliminary design strategy, the c.1448T>C-targeting par-
allel primer matched both gene and pseudogene. The
antiparallel primer was predicted to match the gene but
not pair with the pseudogene at its 3' terminus, a strategy
often used to selectively amplify particular sequences[26].
These predictions were borne out in all cell-line-based
DNA controls assayed (Table 4 and data not shown).
While such controls are helpful as preliminary confirma-
tion of assay experimental design, they are not suffi-
cient[35,36]. Cell line samples may not adequately
represent the range of quality, quantity, and sequence
identity of DNA used in a clinical setting. In contrast to
single-source cell-lines, the genetic diversity of patient
samples with potentially interfering polymorphisms may
affect allele analysis.
Issues surrounding molecular analysis of the GBA gene in
the invariable presence of ΨGBA have been reported[5].
For example, all pseudogene sequences published to date
appear mutant at a site paralogous to the c.1448T>C
mutation in the gene. In an effort to examine this and
Table 5: Nucleotide positions divergent between GBA and ΨGBA
nucleotide positiona
gene sequence 6844 7031 7159 7183 7192 7319 7354 7368
GBA patient 4 Gb A/G C - T T G G
patient 9 G A/G C - T T G G
patient 11 G A/G C - C/T T G G
patient 14 G G C - T T G G
patient 17 G A/G C - T T G G
patient 27 G A/G C - T T G G
NA11215 G A/G C - T T G G
Gen-4.87 G G C G T T G G
UCSC G A C - T T G G
ΨGBA patient 4 C G C/T - C C G/C G/C
patient 9 C G T - C C G/C G/C
patient 11 C G C/T - C C G/C G/C
patient 14 C G C/T - C C G/C G/C
patient 17 C G T - C C C C
patient 27 C G T - C C C C
NA11215 C A/G T - C C C C
Gen-4.87 C A T - C C C C
U C S C CGT -CCCC
aNucleotide positions are consistent with reference sequence [GenBank:J03059.1] (which is equivalent to that reported by the UCSC database for 
the region in question).[16] All nucleotides not listed displayed perfect identity between all nine sequences in the alignment.
bNucleotide designations are G (guanosine), C (cytosine), T (thymidine), and A (adenosine). Observed heterozygous nucleotide positions are 
indicated as A/G, C/T, or G/C.BMC Medical Genetics 2006, 7:69 http://www.biomedcentral.com/1471-2350/7/69
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other polymorphisms and to obtain additional sequence
for quality design, we sequenced GBA and ΨGBA from
multiple DNA samples. As seen in Table 5, nucleotide
6844 (reference sequence [GenBank:J03059.1]) may be a
candidate for reliable differentiation of gene from pseudo-
gene during amplification; however, it offers little benefit
over the 55-bp deletion which is tightly linked upstream
and has been successfully used in techniques that allow
larger amplicons[3-5]. Nucleotide 7031 is not reliable for
the unique amplification of the gene. In fact, the UCSC
database[15,16] and Horowitz et al.[1] report discordant
nucleotide identities at this site. This may be explained by
our observation that some patients display both GBA and
ΨGBA as heterozygous with A/G. Although all patients'
genes exhibited C at nucleotide 7159, two patients' pseu-
dogenes were heterozygous for C, rendering this an unre-
liable universal primer position for primer mispair-based
differentiation. This nucleotide change – observed here in
samples submitted for Ashkenazi carrier screening – has
previously been reported in the Maya population[37]. The
intronic "insertion" G (as compared to ΨGBA) reported
by Horowitz et al.[1,15,16] (nucleotide 7183) is neither
reported in the UCSC database[15,16] nor observed in
our sample set. Although all patients' pseudogenes exhib-
ited C at nucleotide 7192, one patient's gene was hetero-
zygous with C/T, rendering this another nucleotide
position unreliable for differentiation. Nucleotide 7319
corresponds to the locus of interest (c.1448T). As expected
based on previous reports,[1,15-17] all sequenced genes
had T and all pseudogenes had C at this site. No down-
stream nucleotide positions were discovered during this
analysis that could be reliably used for GBA/ΨGBA mis-
pair-based differentiation during amplification.
The data observed at nucleotides 7354 and 7368 sup-
ported our hypothesis that a polymorphism in the primer-
binding site of the pseudogene could allow co-amplifica-
tion with the gene. Four patient samples displayed G in
the gene at these sites and G/C in the pseudogene. Hence,
the four samples that yielded discrepant c.1448T>C heter-
ozygous determinations have sequences in their pseudo-
genes that are predicted to be amplified by our original
primer design. Since pseudogenes from these same
patients were sequence confirmed to contain C at nucleo-
tide 7319, their amplified products are predicted to bind
to c.1448T>C mutant capture probes. This would then be
expected to result in the heterozygous determinations
seen in these patients. Only by using a well established
region of differentiation between GBA and ΨGBA were we
able to reliably enrich for gene-specific amplification.
While this approach created a larger amplified product, it
was sufficient for detection on a suspension bead array
platform.
Conclusion
Our experience demonstrates the limitations of using
publicly-available sequence databases for multiplex assay
design. We conclude that for gene/pseudogene differenti-
ation it may be insufficient to use the sequence informa-
tion currently available without additional clinical
testing. As multiple, unique genomic DNA sequence
information is not always readily available, the sequence
data contributed here should aid in the future design of
genetic assays in this region of GBA. Furthermore, whereas
the available sequence information suggested discrimina-
tion capabilities with a shorter product, we identified a
single-nucleotide polymorphism in the pseudogene that
required the use of a larger product for effective gene/
pseudogene discrimination. We successfully demon-
strated that larger amplified products can be directly
hybridized to bead-bound capture probes in a liquid bead
array. With regards to the complexity of genetic testing
and the increased use of multiplexed platforms, this
report urges caution when designing tests for Gaucher dis-
ease and other genetic assays dependent on the frequency
of SNPs that may not be readily apparent based on current
genomic sequence database releases. This report also
underscores the continued need for thorough clinical
evaluation of new assays prior to adoption into routine
testing. We advocate multiple-laboratory clinical evalua-
tion of assay designs early in the development process to
produce robust and reliable multiplex diagnostic assays.
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